GlassScriptPhysician profile
Zeeshan Qureshi
NPI 1457678401
$12,045.03
in general payments reported to CMS, 2019-2025
39 companies · $3,488 in 2025
The $3,488 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $278 · 2021: $1,230 · 2022: $1,434 · 2023: $2,413 · 2024: $2,697 · 2025: $3,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,355 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,355.41 |
| Education | $243.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,719.34 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,038.23 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,013.65 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $841.90 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $608.29 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $459.36 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $430.55 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $329.10 | 2019-2024 | Dificid |
| Pfizer INC. | $318.60 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $308.49 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $308.30 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $287.98 | 2020-2025 | Linzess |
| Ferring Pharmaceuticals INC. | $283.52 | 2021-2025 | Rebyota, Clenpiq |
| Ardelyx, INC. | $266.30 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $231.48 | 2019-2025 | Ocaliva |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $204.58 | 2021-2025 | Gimoti |
| Genzyme Corporation | $195.42 | 2022-2025 | |
| Madrigal Pharmaceuticals | $167.54 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $157.50 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $120.26 | 2021-2023 | |
| Anx Robotica Corp | $108.60 | 2025 | |
| Redhill Biopharma INC. | $91.84 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $89.77 | 2023-2025 | Idacio, Tyenne |
| Medtronic, INC. | $85.78 | 2024 | Gi Genius |
| Braintree Laboratories, INC. | $67.80 | 2021-2024 | Sutab |
| Celltrion USA INC. | $49.62 | 2023-2024 | Yuflyma, Vegzelma, Zymfentra |
| W. L. Gore & Associates, INC. | $43.05 | 2023 | Gore Synecor Biomaterial |
| Micro-Tech Endoscopy USA, INC. | $40.22 | 2024 | Riteclip |
| Amgen INC. | $28.38 | 2023 | Amjevita, Avsola |
| Alnylam Pharmaceuticals INC. | $24.69 | 2025 | Givlaari |
| Laborie Medical Technologies Corp. | $22.30 | 2024 | Alphaone |
| E.R. Squibb & Sons, L.L.C. | $21.38 | 2022 | |
| Ucb, INC. | $19.70 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.24 | 2019 | |
| Endogastric Solutions, INC | $13.18 | 2019 | |
| Ethicon US, LLC | $12.58 | 2019 | |
| Allergan, INC. | $10.90 | 2019 | |
| Organon LLC | $9.61 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$62,577.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeeshan Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.